Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
-
Patent number: 8404277Abstract: A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer; a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer; and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation.Type: GrantFiled: June 5, 2008Date of Patent: March 26, 2013Assignee: Samyang Biopharmaceuticals CorporationInventors: Jin-Deok Song, Dong-Won Kim
-
Publication number: 20130071483Abstract: The present invention provides an optimized immobilization antigen cDNA sequence of cryptocaryon irritans, which has been processed codon replacement and caused the cDNA to express in prokaryotic and eukaryotic cell and translate a protein has similar immunogenicity as the immobilization antigen purified from the theront of Cryptocaryon irritans. The present invention further provides a DNA vaccine produced using the cDNA to prevent fish form cryptocaryon irritans infection.Type: ApplicationFiled: September 21, 2011Publication date: March 21, 2013Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Yen-Ling Tsai Song, Yen-Hong Lin, Jose Priya Thankaraj Alphonsal
-
Patent number: 8394419Abstract: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods for making DBM bone products, wherein both the DBM and a mineralized gelatin carrier for the DBM are derived independently from a bone lot.Type: GrantFiled: January 6, 2011Date of Patent: March 12, 2013Assignee: Global Medical, Inc.Inventor: Mark Borden
-
Patent number: 8394411Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).Type: GrantFiled: May 1, 2008Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of HealthInventors: Jeff Roberts, Douglas R. Lowy, John T. Schiller
-
Patent number: 8389485Abstract: Methods and compositions for delivering agents (e.g., gene silencing agents) and molecules to cells using yeast cell wall particles are presented herein. Embodiments of the invention are particularly useful for the delivery of nucleic acids (e.g., siRNAs) to cells.Type: GrantFiled: October 29, 2008Date of Patent: March 5, 2013Assignee: University of MassachusettsInventors: Michael P. Czech, Gary R. Ostroff, Myriam Aouadi
-
Patent number: 8383415Abstract: A composition comprising a hydrogel particle and a fluorophore; wherein said composition produces an enhanced fluorescent signal when excited by an energy source capable of exciting the fluorophore.Type: GrantFiled: October 13, 2005Date of Patent: February 26, 2013Assignee: DSO National LaboratoriesInventors: Teck Choon Ayi, Mei-Mei Jill Tong, Vee Sin Peter Lee
-
Patent number: 8372427Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.Type: GrantFiled: March 5, 2007Date of Patent: February 12, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Stephen Dirk Pacetti
-
Patent number: 8367118Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.Type: GrantFiled: July 27, 2012Date of Patent: February 5, 2013Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Scott M. Herbig, James A. S. Nightingale
-
Patent number: 8361509Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: GrantFiled: January 23, 2012Date of Patent: January 29, 2013Assignee: Laboratorios Farmacéticos Rovi, S.A.Inventors: Iván López-Belmonte Encina, Ibon Gutierro Aduriz, Philippe Maincent
-
Patent number: 8357402Abstract: This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth.Type: GrantFiled: July 5, 2011Date of Patent: January 22, 2013Assignee: Integra LifeSciences CorporationInventors: Ronald T. Ingram, Jignesh B. Patel, Timothy J. Pryor
-
Patent number: 8357388Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.Type: GrantFiled: March 3, 2010Date of Patent: January 22, 2013Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Patent number: 8354503Abstract: Process for extracting hydrophobin from a solution wherein carrageenan is added to the solution and the pH of the solution is brought below 3.5, and the ionic strength of the solution is below 0.5.Type: GrantFiled: December 11, 2009Date of Patent: January 15, 2013Assignee: Conopco, Inc.Inventor: Nicholas David Hedges
-
Patent number: 8343551Abstract: Nanocomposite particles having good solubility and redispersibility in water are provided. The nanocomposite particles include a sugar material and nanoparticles containing a drug to be delivered and a biodegradable polymer, the sugar material being disaccharide, and a mass ratio of the nanoparticles to the disaccharide being within the range of from 40:60 to 60:40.Type: GrantFiled: March 16, 2007Date of Patent: January 1, 2013Assignee: Tokyo University of Science Educational Foundation Administrative OrganizationInventors: Kimiko Makino, Hiroshi Terada, Takehisa Nakajima, Keishiro Tomoda
-
Patent number: 8343547Abstract: Provided are a solid dosage form comprising a solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising a solid dispersion, the dispersion comprising: a poorly soluble drug, a water-soluble polymer and a disintegrant, wherein the disintegrant is low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.0 m2/g. Moreover, provided is a method for producing a solid dosage form comprising a solid dispersion, the method comprising steps of: spraying a water-soluble polymer solution in which a poorly soluble drug has been dispersed or dissolved, on a powder of low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.Type: GrantFiled: August 1, 2007Date of Patent: January 1, 2013Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Takafumi Hoshino, Fumie Kusaki, Naosuke Maruyama, Yuichi Nishiyama, Ikuo Fukui, Hiroshi Umezawa
-
Patent number: 8343548Abstract: Provided are a solid dosage form comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising an enteric solid dispersion comprising a poorly soluble drug, an enteric polymer and a disintegrant, wherein the disintegrant is low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.0 m2/g. Moreover, provided is a method for producing a solid dosage form comprising an enteric solid dispersion, the method comprising steps of: spraying an enteric polymer solution in which a poorly soluble drug has been dispersed or dissolved, on a powder of low-substituted hydroxypropylcellulose having an average particle size of 10 to 100 ?m and a specific surface area measured by BET method of at least 1.Type: GrantFiled: August 1, 2007Date of Patent: January 1, 2013Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Fumie Kusaki, Takafumi Hoshino, Naosuke Maruyama, Yuichi Nishiyama, Ikuo Fukui, Hiroshi Umezawa
-
Patent number: 8329225Abstract: The present invention is a method for encapsulating active protein in a polymeric nanocarrier. The instant method employs homogenization at subzero temperatures so that enzyme activity is retained. Enzymes which can be encapsulated by the present method include, for example, antioxidant enzymes and xenobiotic detoxifying enzymes. Encapsulation of an enzyme protects it from protease degradation and increases therapeutic half-life. Advantageously, polymeric nanoparticles of the invention are permeable to enzyme substrates and therefore enzymes encapsulated by the instant method can exert their effect without release from the nanocarrier. Methods for decomposing a reactive oxygen species, protecting against vascular oxidative stress, and detoxifying a xenobiotic are also provided.Type: GrantFiled: June 10, 2009Date of Patent: December 11, 2012Assignee: Trustees of the University of PennsylvaniaInventors: Vladimir R. Muzykantov, Thomas D. Dziubla
-
Publication number: 20120294924Abstract: Disclosed are peptide-lipid conjugates that bind lipopolysaccharide. Also disclosed are methods of making and using the peptide-lipid conjugates.Type: ApplicationFiled: April 24, 2012Publication date: November 22, 2012Inventors: THOMAS TICE, TORSTEN WOEHR
-
Publication number: 20120294948Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.Type: ApplicationFiled: May 14, 2012Publication date: November 22, 2012Inventors: Saravanane Poobalane, Kim THOMPSON, Alexandra ADAMS
-
Patent number: 8314156Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: GrantFiled: March 1, 2011Date of Patent: November 20, 2012Assignee: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Patent number: 8313328Abstract: A periodontal structure regeneration composition for treatment of periodontal disease is a mixture of particles of a bone growth material and free collagen. All particles are sized to be less than 1 mm in diameter. The periodontal regeneration composition is injected into the periodontal pocket through an 18 gauge needle. The composition may contain a thickener that increases the viscosity of the composition after the material has been injected into the periodontal pocket. The composition is available in pre-filled syringes offered in a kit that may also contain strips of surgical sponge or gauze that are sized to fit within a periodontal pocket, a tube of adhesive, a dental bur, a probe, a gauze placement tool, gauze counter and a brush for cleaning the dental bur.Type: GrantFiled: August 28, 2006Date of Patent: November 20, 2012Inventor: Dennis W. Szymaitis
-
Publication number: 20120282343Abstract: The present invention provides nanoparticle compositions comprising a cationic biopolymer and at least one biologically active substance, pharmaceutical compositions comprising such nanoparticles and methods for the oral administration of biologically active molecules which are susceptible to degradation in the gastro-intestinal tract using nanoparticle. The present invention further provides compositions and methods for the oral administration of gene therapy.Type: ApplicationFiled: May 7, 2012Publication date: November 8, 2012Applicant: Johns Hopkins UniversityInventors: Kam W. Leong, Grace Okoli, Gonzalo Hortelano
-
Patent number: 8303987Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.Type: GrantFiled: July 13, 2010Date of Patent: November 6, 2012Assignee: Novartis AGInventors: Oskar Kalb, Stephen Valazza
-
Patent number: 8298561Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.Type: GrantFiled: September 21, 2010Date of Patent: October 30, 2012Assignee: Intarcia Therapeutics, Inc.Inventors: Thomas R. Alessi, Kenneth L. Luskey
-
Patent number: 8287907Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.Type: GrantFiled: November 10, 2006Date of Patent: October 16, 2012Assignee: Phares Pharmaceutical Research, N.V.Inventors: Steve Leigh, Matthew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
-
Patent number: 8277847Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.Type: GrantFiled: February 13, 2009Date of Patent: October 2, 2012Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Rimona Margalit, Dan Peer
-
Patent number: 8277846Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: GrantFiled: May 13, 2011Date of Patent: October 2, 2012Assignees: California Institute of Technology, Calando Pharmaceuticals, Inc.Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
-
Patent number: 8273374Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.Type: GrantFiled: July 29, 2011Date of Patent: September 25, 2012Assignee: MedImmune, LLCInventors: Vu Truong-Le, Binh Pham
-
Patent number: 8273330Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.Type: GrantFiled: April 24, 2003Date of Patent: September 25, 2012Assignee: Nektar TherapeuticsInventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
-
Publication number: 20120231086Abstract: The present invention relates to immunogenic compositions containing an antigen of interest entrapped with a crosslinked carrier protein matrix, methods of making such vaccines, and methods of vaccine administration, wherein the immunogenicity of the protein matrix, and hence its effectiveness as a vaccine, is improved by controlling or selecting the particle size of the protein matrix particles to eliminate low molecular weight particles, e.g., less than 100 nm in diameter.Type: ApplicationFiled: September 9, 2010Publication date: September 13, 2012Inventors: Kevin P. Killen, Thomas J. Griffin, IV, Ann Thanawastien
-
Publication number: 20120225129Abstract: Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.Type: ApplicationFiled: August 18, 2011Publication date: September 6, 2012Applicant: CERULEAN PHARMA INC.Inventors: Scott Eliasof, Oliver S. Fetzer, Jungyeon Hwang, Patrick Lim Soo, Pei-Sze Ng, Sonke Svenson, Donald E. Bergstrom
-
Publication number: 20120225118Abstract: Compositions and methods of making the same for improving the bioavailability of a substantially water-insoluble pharmacologically active agent are described. The composition includes a substantially water-insoluble pharmacologically active agent, and a substantially water-insoluble matrix forming material comprising enzyme digestible or bile soluble nutrients, wherein the substantially water-insoluble pharmacologically active agent is dispersed in a solid matrix and wherein said pharmacologically active agent in said matrix is substantially free of the original crystalline form.Type: ApplicationFiled: February 23, 2012Publication date: September 6, 2012Applicant: Latitude Pharmaceuticals IncorporatedInventors: Hailiang Chen, Andrew Xian Chen
-
Patent number: 8257741Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.Type: GrantFiled: June 9, 2003Date of Patent: September 4, 2012Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Scott M. Herbig, James A. S. Nightingale
-
Patent number: 8257744Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: GrantFiled: May 13, 2010Date of Patent: September 4, 2012Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ivan Lopez-Belmonte Encina, Ibon Gutierro Aduriz, Philippe Maincent
-
Patent number: 8257785Abstract: A method for producing a composite nanoparticle, including the steps of: changing the conformation of a dissolved polyelectrolyte polymer from a first extended conformation to a more compact conformation by changing a solution condition so that at least a portion of the polyelectrolyte polymer is associated with a precursor moiety to form a composite precursor moiety with a mean diameter in the range between about 1 nm and about 100 nm; and cross-linking the polyelectrolyte polymer of the composite precursor moiety to form a composite nanoparticle.Type: GrantFiled: June 17, 2011Date of Patent: September 4, 2012Assignee: Vive Crop Protection, Inc.Inventors: Cynthia M. Goh, Jose Amado Dinglasan, Jane B. Goh, Richard Loo, Darren Anderson
-
Patent number: 8252338Abstract: The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so as to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of incorporating and targeting therapeutics to cells expressing the LDL receptor for diseases associated with the expression of the LDL receptor such as central nervous system diseases. The invention further provides methods of using such synthetic LDL nanoparticles.Type: GrantFiled: November 13, 2006Date of Patent: August 28, 2012Assignees: The Regents of the University of California, Children's Hospital & Research Center OaklandInventors: Trudy M. Forte, Mina Nikanjam
-
Patent number: 8252322Abstract: The present invention is directed to a dry composition which allows delivery of active agents with good bioavailability. These compositions are prepared by emulsifying the active agent using liposome technology known in the art and then encapsulating with a modified starch. The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group. The resultant composition is a dry powder with excellent bioavailability. Further, the composition has good load levels and stability.Type: GrantFiled: June 3, 2003Date of Patent: August 28, 2012Assignee: Corn Products Development, Inc.Inventors: Paolo C. Trubiano, Afaf Karras
-
Publication number: 20120213848Abstract: A method for treating HIV and other intra-cellular parasites and toxins using intrabodies delivered to leukocytes.Type: ApplicationFiled: November 16, 2011Publication date: August 23, 2012Inventor: Brian P. Hanley
-
Patent number: 8246975Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.Type: GrantFiled: June 28, 2007Date of Patent: August 21, 2012Assignees: IHI CorporationInventors: Haruki Eguchi, Yoshihiro Ishikawa
-
Publication number: 20120207846Abstract: Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures.Type: ApplicationFiled: November 21, 2008Publication date: August 16, 2012Inventors: Xueyun GAO, Yi SUN
-
Patent number: 8241609Abstract: A method for embolization using liquid embolic materials is described. The method comprises the use of two liquid components. The first liquid component is an aqueous solution or dispersion comprising at least one oxidized polysaccharide. The second liquid component is either an aqueous solution or dispersion comprising at least one water-dispersible, multi-arm amine, or a water-dispersible multi-arm amine in the form of a neat liquid. The two components crosslink in situ to form a hydrogel that should act as an effective embolic agent.Type: GrantFiled: August 20, 2008Date of Patent: August 14, 2012Assignee: E I du Pont de Nemours and CompanyInventors: Garret D. Figuly, Llewellyn Bentley Richardson, III
-
Publication number: 20120201873Abstract: The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.Type: ApplicationFiled: August 5, 2010Publication date: August 9, 2012Applicant: PIERIS AGInventors: Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Sankaram Bhima Mantripragada, Kathleen Marie Campbell
-
Patent number: 8221794Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Type: GrantFiled: March 3, 2010Date of Patent: July 17, 2012Assignee: Angiotech Pharmaceuticals, Inc.Inventors: William L. Hunter, Lindsay S. Machan, A. Larry Arsenault, Helen M. Burt, John J. Jackson, Stephen K. Dordunoo
-
Patent number: 8211475Abstract: A method for preparing chitosan nanoparticles in water phase is provided. The method comprises the following steps: (a) providing a chitosan solution having a concentration of about 0.05 w/v % to about 1 w/v %, (b) adding water first and then followed by acetic anhydride to the chitosan solution to carry out acetylation, wherein the concentration of acetic anhydride is from about 10 v/v % to about 30 v/v % of the total volume of the whole solution, and (c) subjecting the solution from step (b) to physical dispersion.Type: GrantFiled: November 6, 2008Date of Patent: July 3, 2012Assignee: Food Industry Research and Development InstituteInventors: Ke-Ming Liang, Yen-Lin Chen, Mei-Huei Chen, Hing-Yuen Chan
-
Publication number: 20120164234Abstract: The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.Type: ApplicationFiled: September 16, 2011Publication date: June 28, 2012Applicant: ALLTECH, INC.Inventors: Stefan Kwiatkowski, Ronan Power, Clayton Matney, Paiman Peter Ghoroghchian, Eric Michael Ostertag
-
Patent number: 8206748Abstract: A powdery composition for nasal administration, where (1) the composition contains (i) a drug, (ii) a water-absorbing and gel-forming base material such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose and (iii) a water-absorbing and water-insoluble base material such as crystalline cellulose or ?-cellulose, (2) wherein the amount of the water-absorbing and gel-forming base material is about 5-40 wt % based on the total of the water-absorbing and gel-forming base material and the water-absorbing and water-insoluble base material, and (3) wherein the drug is unevenly dispersed more on/in the water-absorbing and water-insoluble base material than on/in the water-absorbing and gel-forming base material.Type: GrantFiled: November 2, 2009Date of Patent: June 26, 2012Assignee: Teijin LimitedInventors: Masahiko Dohi, Yoshihisa Nishibe, Yuji Makino, Takao Fujii
-
Publication number: 20120156305Abstract: The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing the genome stability in a population of ES or iPS cells, increasing telomere length in a population of ES or iPS cells, or both, are provided, for example by selecting Zscan4+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4+ and Zscan4? ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.Type: ApplicationFiled: September 2, 2010Publication date: June 21, 2012Inventors: Minoru S.H. Ko, Michal Zalzman, Lioudmila V. Sharova
-
Patent number: 8202540Abstract: The invention relates to superfine microparticles and nanoparticles and a process for their gentle preparation with exclusion of water or minimization of water and/or exclusion of plasticizers and/or reduced temperature load, in which a matrix material is subjected to a high-pressure homogenization process in an anhydrous or water-poor medium and/or at low temperatures, preferably room temperature (20° C.) and in particular below the freezing point of water, which leads to a gentle particle reduction with minimization of the impairment of the chemical stability of the homogenized material.Type: GrantFiled: July 10, 2000Date of Patent: June 19, 2012Assignee: Abbott GmbH & Co., KGInventors: Rainer H. Müller, Karsten Krause, Karsten Mäder
-
Patent number: 8202544Abstract: Non-viral vectors for delivering agents to a site within the body of an animal comprise a biocompatible nanoparticle conjugated to an avidin/biotin complex and a water soluble linear polymer comprising multiple binding sites. The agents to be delivered are conjugated to each of the multiple binding sites, thereby increasing the loading capacity of the system. Where the agents comprise siRNA, each biotin/avidin complex may carry greater than four siRNA. The biocompatible nanoparticle may also comprise a fluorescent dye for in vivo imaging.Type: GrantFiled: September 18, 2009Date of Patent: June 19, 2012Assignee: Carestream Health, Inc.Inventors: Rao Papineni, Tao Ji, William E. McLaughlin
-
Publication number: 20120134919Abstract: A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself.Type: ApplicationFiled: August 4, 2010Publication date: May 31, 2012Applicant: BIOMATCELL ABInventors: Hakan Engqvist, Wei Xia
-
Publication number: 20120128752Abstract: The invention relates to a method of manufacturing multi-phase microparticles. The method comprises dissolving at least three different polymers in a volatile organic solvent to obtain a first solution. The first solution comprises at least two cloud points, wherein the second cloud point is higher than the first cloud point. Viscosity of the first solution and the first and second cloud point are selected such that the at least three different polymers are immiscible with each other in the first solution. The first solution is dispersed into an aqueous continuous phase which comprises a surfactant to obtain an emulsion. The volatile organic solvent is evaporated from the emulsion. The total concentration of the at least three different polymers together in the emulsion before evaporation is below the first cloud point, or is above the first cloud point and below the second cloud point or is above the second cloud point.Type: ApplicationFiled: June 7, 2010Publication date: May 24, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Say Chye Joachim Loo, Wei Li Lee